Product Design Concept ： InSeed Pure Smoothness is a probiotic powder targeting metabolic and gut health. Developed under Prof. Tsai Ying-Chieh, it features K21 and MetSyn strains to tackle microbiota imbalance, digestive strain, and metabolic issues from dining-out and poor diets. It enhances gut flora, boosts metabolism, and uses dual prebiotics and triple enzymes to maintain daily health and body shape.
Key Technologies
K21™: L. plantarum K21™, screened from 88 strains, maintains microbiota and metabolic balance. Patented in US, TW, CN, and HK.
MetSyn: L. acidophilus PBS066, L. reuteri PBS072, and L. plantarum PBS067 from ROELMI·HPC optimize flora and metabolism. Won NutraIngredients Awards 2021 for Weight Management.
LGG: L. rhamnosus GG is backed by hundreds of papers for gut balance and immune regulation.
Synbiotics: Inulin and soluble corn fiber boost probiotic survival.
Enzymes: Amylase, lipase, and protease break down food to enhance nutrient absorption.
Scientific & Safety Assurance：Developed by Prof. Tsai’s team with studies published in peer-reviewed journals. Manufactured by ISO22000, HACCP, and TQF-certified "Hong Zhong Biotechnology". It undergoes regular third-party tests for microbes, heavy metals, and plasticizers to ensure safety.
The contract manufacturer of this product, "Hong Zhong Biotechnology Co., Ltd." (established in 2008), is a renowned OEM factory equipped with rigorous quality control infrastructures. The manufacturing facility has successfully obtained major international and domestic food safety certifications, including:
ISO 22000 (International Food Safety Management System Certification).
HACCP (Hazard Analysis Critical Control Point System Verification).
TQF (Taiwan Quality Food Association Certification).
Health Food GMP (Good Manufacturing Practice Verification). The product compliant with domestic food safety regulations and aligns with international quality assurance protocols.
Inulin, Soluble Corn Fiber, Yogurt Powder [Sugar, Yogurt Fermentation Liquid (Sucrose, Fructose, Milk Powder, Flavor, Lactic Acid, Soybean Fiber, Lactic Acid Bacteria), Sodium Octenyl Succinate Starch, Condensed Milk, Lactic Acid, Corn Starch, Sodium Citrate, Citrus Pectin (Citrus Pectin, Sucrose), Yogurt Flavor (including Orange Peel Oil), Citric Acid, Lemon Flavor Powder], Probiotic Complex (Lactobacillus plantarum K21™, Lactobacillus rhamnosus GG, Lactobacillus acidophilus PBS066, Lactobacillus reuteri PBS072, Lactobacillus plantarum PBS067), Digestive Enzymes Complex (Maltodextrin, Protease, Lipase, Amylase).
The active ingredient for health claims in this product is the "Total Lactic Acid Bacteria Count", which consists of the following strains:
Patented Metabolic Strain: Lactobacillus plantarum K21™.
Widely Researched Strain: Lactobacillus rhamnosus GG.
MetSyn Probiotic Complex: Lactobacillus acidophilus PBS066, Lactobacillus reuteri PBS072, and Lactobacillus plantarum PBS067.
[Active Content Specification] Each serving (1 sachet of 2 grams) guarantees a minimum active lactic acid bacteria count of 1x10¹⁰CFU/sachet (10 Billion CFU per sachet) at release. The raw probiotic materials and final products undergo strict microbial analysis to ensure that the active ingredient content meets the health-promoting threshold consistently.
Hong Zhong Biotechnology Co., Ltd.
The quality control system operates as a closed-loop mechanism managed by dedicated QA/QC personnel across three main stages:
Raw Material Inspection: Key probiotic materials are stored at -18°C and transported via cold-chain logistics. Inspection involves matching batch codes, expiry dates, and verifying COA data. Food additives are cross-checked with official government permits before storage.
In-Process & Semi-Finished QC: Following the QC engineering chart, during the mixing and filling stage, semi-finished products are strictly evaluated based on appearance, color, moisture levels, and weight. Data is compiled into control logs; subsequent packaging is only approved upon passing.
Finished Product & Shipping Release: Finished goods are sampled for packaging compliance (inkjet printing, film shrinkage) and quantitative parameters (moisture, water activity, weight tolerances). Critical microbial screening (Coliforms, E. coli, molds, and yeasts) is conducted based on TFDA safety methods.
Stability Monitoring: Annual random sampling of finished product batches is scheduled for long-term storage stability trials to verify the quantified indicators remain premium throughout the 2-year shelf life.
In strict accordance with the Act Governing Food Safety and Sanitation, the product undergoes rigorous safety testing. Probiotic raw materials are checked batch-by-batch internally. For finished products, the company commissions TFDA-certified third-party laboratories (e.g., Intertek) annually to conduct safety testing on the latest production batch (e.g., Batch: HS27040101). The certified testing spectrum includes:
Microbial Compliance (Mandatory): Testing for Coliforms and Escherichia coli to meet sanitary criteria.
Pathogen Screening: Testing for Staphylococcus aureus and Salmonella.
Heavy Metals (Mandatory): A 4-item heavy metal panel analyzing Lead (Pb), Cadmium (Cd), Mercury (Hg), and Arsenic (As) levels.
Plasticizers: A 9-item screening for common chemical phthalate plasticizers.
Adulterated Western Pharmaceuticals: Screening for undeclared Western drugs to ensure zero chemical adulteration.
Pesticide Residues: A comprehensive pesticide residue scan ensuring pure botanical and raw material sources. All test certificates of analysis (COA) are issued within one year, demonstrating safety verification.
A cross-departmental closed-loop risk management framework is established to control potential hazard variables at every stage:
1. Materials & In-Process Control:
Raw materials are sourced from audited vendors. Probiotics are monitored under strict temperature controls (-18°C). During production, QA line inspections review half-finished mixtures for consistency, weight variation, and moisture anomalies to prevent sub-standard blending.
2. Finished Product Release & Lab Auditing:
Internal laboratory personnel are trained in ISO17025 and Food Probiotics GMP courses. No batch is released into commercial warehouses unless double-verified against factory COAs and internal verification parameters. Annual proficiency testing is executed to eliminate testing errors.
3. Post-Market Vigilance & Complaint SOP:
Customer service logs user feedback within 24 hours, channeling complaints regarding texture or packaging directly to the QA department. Remedial actions and root-cause analyses are mandated to prevent recurring issues.
4. Crisis Management & Recall Protocols:
Systemic production flaws are mathematically defined (e.g., >2 sachets clumped in an unopened box across >2 distinct consumer complaints within 3 months). Once triggered, the crisis team assesses product safety, executes market recall procedures across all D2C/retail channels, and reports to the Taiwan Food and Drug Administration (TFDA).
The efficacy of the core strains is backed by peer-reviewed animal models and double-blind, randomized, placebo-controlled human clinical trials:
1. Lactobacillus plantarum K21™ Evidence:
Screened from 88 strains, K21 hydrolyzes bile salts, lowers cholesterol by >50%, and inhibits lipid accumulation in 3T3-L1 preadipocytes. In DIO mice fed a high-fat diet for 8 weeks, K21 significantly reduced weight gain and epididymal fat pad accumulation. It lowered plasma cholesterol, triglycerides, AST, and ALT, alleviating hepatic steatosis while normalizing liver PPAR-γ mRNA expression. K21 also restored gut permeability (via FITC-dextran), enhanced the intestinal barrier, increased cecal Bifidobacterium and Lactobacillus, and decreased Clostridium perfringens.
2. MetSyn Probiotic Complex Clinical Trial:
Formulated with L. acidophilus PBS066, L. reuteri PBS072, and L. plantarum PBS067, cell studies show inhibition of HMG-CoA reductase. A randomized, placebo-controlled trial on 60 elderly subjects (65–80 years old) with metabolic syndrome showed that a daily dose of 6x10⁹ CFU for 60 days reduced waist circumference, visceral fat, and mean arterial pressure. It decreased LDL-C, triglycerides, TNF-alpha, and hs-CRP, while increasing HDL-C and improving insulin sensitivity. Another trial verified that 1x10⁹ CFU daily for 60 days significantly relieved bloating and gas while normalizing bowel habits in IBS patients.
Here is the professional English translation, meticulously tailored and condensed to stay safely under the strict 1,500-character limit (including spaces), making it ready for your SNQ online submission:
L. plantarum K21: Published in Evidence-Based Complementary and Alternative Medicine, titled "Effect of Lactobacillus plantarum Strain K21 on High-Fat Diet-Fed Obese Mice". It proves K21 inhibits weight gain, lowers blood lipids and liver fat accumulation, and regulates the gut microbiota barrier in obese mice.
MetSyn Clinical Trial: Published in European Journal of Nutrition, titled "Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial". It proves the strains reduce visceral fat, improve blood lipids, and alleviate systemic inflammatory responses (TNF-alpha, hsCRP) in elderly patients with metabolic syndrome.
MetSyn Gut Relief Trial: Published in BioMed Research International, titled "A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation". It proves continuous consumption significantly relieves IBS symptoms and bloating while promoting regular bowel movements.
The R&D team also collaborates with global authorities like Harvard University, with findings published in high-impact journals such as Nutrients and Food & Function.
InSeed places immense strategic focus on intellectual property, establishing an extensive international patent portfolio for its functional ingredients. The primary metabolic strain, Lactobacillus plantarum K21™, has been granted multiple invention patents worldwide for its novel immunomodulatory, anti-inflammatory, and gut-regulation applications. The verified patent listing includes:
Taiwan Invention Patent: "A novel lactic acid bacteria and its applications in immunomodulation and anti-inflammation", Patent No: I522464 (Status: Granted).
United States Patent: "A NOVEL LACTIC ACID BACTERIA AND ITS APPLICATIONS IN IMMUNOMODULATION AND ANTI-INFLAMMATION", Patent No: US 9,399,048 B2 (Status: Granted).
China Invention Patent: "A novel lactic acid bacteria and its applications in immunomodulation and anti-inflammation", Patent No: ZL 201510098957.9 (Status: Granted).
Hong Kong Patent: "A novel lactic acid bacteria and its applications in immunomodulation and anti-inflammation", Patent No: HK121439 (Status: Granted).
Co-formulated Fibersol-2 Fiber Patents: o US Patents: US 5,380,717 (Large bowel regulation), US 5,620,873 (Dextrin processing), US 5,472,732 (Indigestible dextrin), US 5,430,141 (Low calorie dextrin), US 5,358,729, US 5,264,568. o Japan Patents: JP 平3-47832, JP 平2-154664.
These patents provide robust technical exclusivity and safeguard its competitive advantage in the global commercial marketplace.
